Wang Hai-Yan, Zhu Mo-Li, Hou Ya-Wei, Han Ming-Ming, Zhang Lei
The Second Affiliated Hospital of Shandong University Jinan 250000, Shandong, China.
Shandong University of Traditional Chinese Medicine Jinan 250355, Shandong, China.
Am J Transl Res. 2024 Jul 15;16(7):2877-2888. doi: 10.62347/MZGO7330. eCollection 2024.
This study aims to elucidate the mechanism of action and impact of the "Xuanshen Yishen Mixture" (XYM) on hypertension.
Active components were identified and potential targets were predicted using the Traditional Chinese Medicine Systems Pharmacology database. Hypertension-related targets were collected from GeneCards, DRUGBANK, OMIM, TTD, and PharmaGKB databases. Intersections of disease and drug targets were visualized using the R package "VennDiagram". A protein-protein interaction network was established via the STRING database. GO function enrichment and KEGG pathway analyses were conducted using "clusterProfiler", while "Cytoscape" was used to construct a "drug-component-target" network. Additionally, data from 60 patients with essential hypertension from the Affiliated Hospital of Shandong University of Traditional Chinese Medicine were retrospectively analyzed. Patients were divided into a control group (n = 30) and an XYM group (n = 30) based on treatment regimen.
Sixty active ingredients and 98 related targets were identified from Uncaria, Radix Scrophulariae, and Epimedium in hypertension treatment. Key active components such as quercetin, kaempferol, yohimbine, and beta-sitosterol were pinpointed, with PTGS2, PTGS1, AR, DPP4, and F2 as crucial targets. KEGG pathway analysis highlighted significant pathways including IL-17 signaling, TNF signaling, Relaxin signaling, and HIF-1 signaling. Clinical data indicated that XYM's therapeutic effects are comparable to those of valsartan, which significantly reduced diastolic and systolic blood pressure and demonstrated good biosafety.
Uncaria, Radix Scrophulariae, and Epimedium effectively mitigate hypertension through multiple components, targets, and pathways. Additionally, DPP4, IL-17, and TNF-α are identified as potential therapeutic targets for traditional Chinese medicine preparations in hypertension treatment. This study provides a foundation for further investigation into XYM's mechanisms in hypertension management.
本研究旨在阐明“玄参益肾合剂”(XYM)治疗高血压的作用机制及影响。
利用中药系统药理学数据库鉴定活性成分并预测潜在靶点。从GeneCards、DRUGBANK、OMIM、TTD和PharmaGKB数据库收集高血压相关靶点。使用R包“VennDiagram”可视化疾病和药物靶点的交集。通过STRING数据库建立蛋白质-蛋白质相互作用网络。使用“clusterProfiler”进行GO功能富集和KEGG通路分析,同时使用“Cytoscape”构建“药物-成分-靶点”网络。此外,对山东中医药大学附属医院60例原发性高血压患者的数据进行回顾性分析。根据治疗方案将患者分为对照组(n = 30)和XYM组(n = 30)。
在高血压治疗中,从钩藤、玄参和淫羊藿中鉴定出60种活性成分和98个相关靶点。确定了槲皮素、山奈酚、育亨宾和β-谷甾醇等关键活性成分,PTGS2、PTGS1、AR、DPP4和F2为关键靶点。KEGG通路分析突出了包括IL-17信号通路、TNF信号通路、松弛素信号通路和HIF-1信号通路在内的重要通路。临床数据表明,XYM的治疗效果与缬沙坦相当,显著降低了舒张压和收缩压,并显示出良好的生物安全性。
钩藤、玄参和淫羊藿通过多种成分、靶点和通路有效减轻高血压。此外,DPP4、IL-17和TNF-α被确定为中药制剂治疗高血压的潜在治疗靶点。本研究为进一步研究XYM治疗高血压的机制提供了基础。